Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France.

ABSTRACT:

Introduction

The aim of the current study is to estimate the cost-effectiveness of adjuvant treatment with nivolumab relative to clinically relevant comparators in adult patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection from a French societal perspective.

Methods

The comparators were observation, low-dose interferon and pembrolizumab. A subgroup analysis was carried out in patients with BRAF mutation, adding dabrafenib plus trametinib. A three-state partitioned survival model was developed to project costs and health benefits over a 20-year time horizon. Extrapolation for recurrence-free survival (RFS) and overall survival (OS) was carried out using spline-based models. Because of the immaturity of OS data in pivot

SUBMITTER: Bregman B 

PROVIDER: S-EPMC7649185 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature